Policy Developments - The National Healthcare Security Administration (NHSA) is soliciting public opinions on the draft adjustment plan for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance drug catalog, as well as the commercial health insurance innovative drug catalog [2] - The first version of the commercial health insurance innovative drug catalog will be established in 2025, focusing on innovative drugs with high clinical value that cannot be included in the basic catalog [2] Drug and Device Approvals - JinSai Pharmaceutical's monoclonal antibody drug, Firsekibart, has been approved for the treatment of acute gouty arthritis in adults who are intolerant to or have contraindications for non-steroidal anti-inflammatory drugs and/or colchicine [4] - Betta Pharmaceuticals' innovative drug, Tazemetostat, has been approved for the treatment of locally advanced or metastatic breast cancer in adults who have progressed after endocrine therapy [5] - Xiansheng Pharmaceutical's monoclonal antibody, Suweisitabant, has been approved for the treatment of recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in adults who have received no more than one prior systemic therapy [6] Capital Markets - Merida Biosciences, a U.S. biotech company, has raised $121 million in Series A financing, setting a record for Series A funding in the autoimmune field [8] Industry Events - Former Takeda China President, Dan Guohong, will join BeiGene as General Manager for Greater China, Central Asia, and South Asia, starting August 18, 2025 [10] - Yuan Dong Bio's independent director, Peng Long, is under disciplinary review and investigation for serious violations of discipline and law [12] - KangLe WeiShi announced that its shareholder, Tianlangxing Holdings Group, has reduced its holdings by 1.6953 million shares, accounting for 0.6034% of the company's total share capital [13]

Group 1 - The current market sentiment score is 63, indicating a "relatively hot" market condition, which suggests a gradual upward trend supported by recent improvements in market sentiment and policy [5][11]. - The report highlights three key themes: photovoltaic, energy metals, and innovative pharmaceuticals, with specific companies identified for potential investment opportunities [6]. Group 2 - In the photovoltaic sector, leading domestic glass manufacturers plan to collectively reduce production by 30% starting in July, which is expected to improve the supply-demand imbalance and decrease domestic glass production to around 45GW [6]. - In the energy metals sector, the Democratic Republic of Congo has extended a temporary ban on cobalt exports for an additional three months due to high inventory levels, impacting companies like Huayou Cobalt and Tianqi Lithium [6]. - The innovative pharmaceuticals theme is supported by new measures from the National Healthcare Security Administration to enhance the use of medical insurance data in drug development, benefiting companies such as Heng Rui Medicine and BeiDa Pharmaceutical [6].

Group 1: Market and Economic Indicators - In June, the A-share market saw 1.65 million new accounts opened, bringing the total for the first half of the year to 12.6 million, a year-on-year increase of 32.77% compared to 9.49 million in the same period of 2024 [1] - The logistics industry in China reported a logistics prosperity index of 50.8% in June, up 0.2 percentage points from the previous month, indicating continued expansion in logistics business volume [1] - The Shanghai real estate market showed signs of recovery, with total transactions of new and second-hand housing reaching 1.311 million square meters in the first half of the year, a 17% increase year-on-year [1] Group 2: Company Announcements - Lixun Precision plans to issue shares overseas (H-shares) and list on the Hong Kong Stock Exchange [4] - Nanjing Shanglv expects a net profit decline of 67% to 78% year-on-year for the first half of the year [4] - Kaimeteqi reports normal operating conditions with no undisclosed significant matters [4] - Chengbang Co. states that its subsidiary, Xincun Electronics, currently has a small business scale [4] - Changchun High-tech's subsidiary, Fuxin Qibai monoclonal antibody for injection, has been approved for market entry in China [4] - Ruikang Pharmaceutical's director and vice president Li Zhe has been placed under detention [4] - Yonghui Supermarket reports that JD Shimao has reduced its stake in the company by 1.26% during the reduction period [4] - Betta Pharmaceuticals received approval from the National Medical Products Administration for the market application of Tartrate Teriparatide Capsules [4] - Hainan Highway plans to acquire a 51% stake in Jiaokong Petrochemical, which is expected to constitute a major asset restructuring [4]

Regulatory News - The China Securities Regulatory Commission emphasizes maintaining market stability as a primary regulatory task and promotes the establishment of a normalized market stabilization mechanism [1][5] - Starting from August 1, cash purchases of gold exceeding 100,000 yuan will need to be reported [2][3] Industry News - In June, 1.65 million new A-share accounts were opened, representing a year-on-year increase of 53% [2][6] - The Guangzhou Housing Provident Fund Management Center is soliciting opinions on a draft policy for converting commercial loans to public housing loans when the personal loan rate is below 75% [7] - The Shanghai superconducting material and headquarters base, with an investment of 2.5 billion yuan, has officially started construction, marking it as the largest project in the superconducting field globally [8] - The average wholesale price of eggs in Beijing decreased by 11.23% month-on-month and 26.43% year-on-year in June [7] Company News - Luxshare Precision announced plans for overseas share issuance (H-shares) and listing on the Hong Kong Stock Exchange [10] - Yonghui Supermarket reported that JD World Trade has reduced its stake in the company by 1.26% during the reduction period [10] - Jiangnan Water announced that Lianan Life Insurance has increased its stake in the company through the secondary market [10] - Guizhou Moutai has repurchased 3.3821 million shares as of the end of June, with a total expenditure of 5.202 billion yuan [11] - Tianqi Lithium announced a lawsuit against Yongtai Technology for commercial secret infringement, with expected economic losses of 888 million yuan [13]

Group 1 - Guizhou Moutai has repurchased a total of 3.3821 million shares as of June 30, 2025, accounting for 0.2692% of the total share capital, with a total expenditure of 5.202 billion yuan [2] - Luxshare Precision is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global financing capabilities and governance transparency [2] - Huazhong Xinchuang has received a project notification from a leading domestic eVTOL manufacturer for the development and supply of an intelligent cockpit multimedia display system [3] Group 2 - Meinohua expects a net profit of 46 million to 52 million yuan for the first half of 2025, representing a year-on-year increase of 142.84% to 174.52% [4] - Jiangnan Water has received a report from shareholder Lianan Life Insurance indicating an increase in shareholding by 46.99 million shares, representing 5.03% of the total share capital [5] - Huasen Pharmaceutical has received approval for clinical trials of its CX001 sustained-release tablets, marking a milestone for its innovative drug development platform [6] Group 3 - Zongshen Power anticipates a net profit growth of 70% to 100% for the first half of the year [7] - Yutong Bus reported a sales volume of 5,919 units in June, a year-on-year increase of 24.79% [7] - Guangzhou Port expects a 7.0% year-on-year increase in container throughput for June 2025 [7] Group 4 - Data Port's shareholders plan to reduce their holdings by up to 1.74% and 0.26% of the company's shares [9] - Humanwell Healthcare's shareholder plans to increase its stake by 1% to 2% [9] - Nengte Technology plans to repurchase shares worth between 300 million to 500 million yuan [10]

贝达药业股份有限公司 关于国家药品监督管理局批准酒石酸泰瑞西利胶囊上市的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 今日，国家药品监督管理局（以下简称"国家药监局"）官方网站公示， 国家药监局批准贝达药业股份有限公司（以下简称"公司"）申报的酒石酸泰 瑞西利胶囊（BPI-16350，商品名：康美纳®，以下简称"泰瑞西利"）上市， 现将具体情况公告如下： 证券代码：300558 证券简称：贝达药业 公告编号：2025-048 适应症：本品联合氟维司群，适用于既往接受内分泌治疗后进展的激素受体 （HR）阳性、人表皮生长因子受体 2（HER2）阴性的局部晚期或转移性成年乳腺 癌患者。 二、药品基本情况及同类药品市场状况 泰瑞西利是由公司自主研发的全新的、拥有完全自主知识产权的新分子 实体化合物，针对的靶点为细胞周期蛋白依赖性激酶 4/6（CDK4/6）。CDK4/6 是调节细胞周期的关键因子，能够触发细胞周期从生长期（G1 期）向 DNA 复制 期（S 期）转变，泰瑞西利能特异性地和 CDK4/6 结合而抑制其激酶活性，抑制癌 细胞增殖、转移等相关的信号传 ...

Group 1 - CITIC Construction Investment has received approval from the China Securities Regulatory Commission to issue perpetual subordinated bonds with a total face value of no more than 20 billion yuan [1] - Bluefocus Technology has received a loan commitment of up to 900 million yuan from CITIC Bank for stock repurchase [1] - Huaren Pharmaceutical's subsidiary has received approval for the listing of Bumetanide raw materials, which are used to treat severe heart failure and hypertension emergencies [3] Group 2 - Betta Pharmaceuticals has received approval for the listing of Enasidenib capsules in Macau, aimed at treating ALK-positive locally advanced or metastatic non-small cell lung cancer [4] - Juewei Food plans to use 110 million yuan of idle fundraising for cash management, with an expected annual yield of 1.00%-1.89% [6] - China Huadian has successfully completed the issuance of 1 billion yuan medium-term notes with a coupon rate of 1.95% [9] Group 3 - Fosun Pharma's subsidiary has received a GMP certificate from the Belgian Federal Agency for Medicines and Health Products for the production facilities of two monoclonal antibodies [11] - China Nuclear Engineering has signed a civil engineering contract for the Taishan Nuclear Power Units 3 and 4 [13] - Kanglongda has faced administrative regulatory measures from the Zhejiang Securities Regulatory Bureau due to the failure of performance commitment parties to fulfill compensation obligations [15] Group 4 - Gaoling Information has received three invention patent certificates in the second quarter, covering various technological fields [16] - Weimais plans to use 190 million yuan of excess fundraising to increase capital in its subsidiary for building a new energy vehicle powertrain production base [17] - Huazhong Technology has received a project designation notice from a leading eVTOL manufacturer for the development and supply of an intelligent cockpit multimedia display system [19] Group 5 - Madi Technology expects a net profit of 25 million to 27 million yuan for the first half of 2025, marking a turnaround from a loss in the previous year [19] - Dazhong Mining's subsidiary has obtained a mining license for the Zhouyoufang Iron Mine, increasing production capacity to 6.5 million tons per year [20] - Zhongguancun's subsidiary has had its application for the listing of Arolol hydrochloride tablets accepted by the National Medical Products Administration [21] Group 6 - Tianhong Co. has signed a property management contract worth 15 million yuan with a local company [22] - Dong'an Power has secured nine new market designation agreements in the second quarter, with a projected total sales volume of 1.5 million units [24] - Zhujiang Co. has appointed Zhao Kun as the new deputy general manager [25] Group 7 - Jinyi Industrial has won a bid for a project worth 335 million yuan from the China Railway Shanghai Bureau Group [26] - Kangchen Pharmaceutical has received a clinical trial notification for its innovative drug KC1086, aimed at treating advanced solid tumors [27] - Changhua Group has received a project designation notice from a new energy vehicle company, with an expected total sales amount of 970 million yuan [29] Group 8 - Lingxiao Pump Industry plans to use 60 million yuan of idle funds to purchase financial products [31] - Mould Technology has received a project designation for exterior parts from a well-known North American electric vehicle company, with an expected total sales of 1.236 billion yuan [34] - Fulongma has pre-bid for five sanitation service projects in June, with a total contract amount of 181 million yuan [35] Group 9 - Changchun High-tech plans to issue H-shares and list on the Hong Kong Stock Exchange [36] - *ST Yuancheng is under investigation by the CSRC for suspected false financial disclosures [37] - Beilu Pharmaceutical's subsidiary has received approval for the listing of Iopamidol raw materials [38] Group 10 - Zhejiang Liming's shareholder plans to reduce their stake by up to 2.93% [39] - Zhejiang Liming's actual controller has committed not to reduce their holdings within a year [40] - SAIC Motor reported a total vehicle sales of 2.0526 million units in the first half of 2025, a year-on-year increase of 12.35% [41] Group 11 - Xinhongcheng expects a net profit increase of 50%-70% for the first half of 2025 [42] - Xianhe Co. plans to invest 11 billion yuan in a bamboo pulp paper integrated project [42] - Great Wall Motors reported a total vehicle sales of 569,800 units in the first half of 2025, a year-on-year increase of 1.81% [43] Group 12 - Dongfeng Co. received a government subsidy of 10 million yuan [44] - Zhongke Environmental Protection has acquired two water environmental companies in Guangxi for a total of 353 million yuan [45] - Anji Food's H-share public offering is priced at 60 Hong Kong dollars per share [46]

Core Viewpoint - The approval of Enasidenib capsules (brand name: Beimingna) by the Macao Drug Regulatory Authority marks a significant milestone for the company in treating ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) patients [1] Group 1: Product Development and Approvals - Enasidenib is a new generation ALK inhibitor developed jointly by the company and its subsidiary Xcovery [1] - The drug received approval for second-line indications from the National Medical Products Administration of China in November 2020 [1] - In March 2022, the first-line indication was approved, followed by the approval for clinical trials of postoperative adjuvant therapy in April 2022, with ongoing Phase III clinical research [1] Group 2: Market Access and Insurance Inclusion - Enasidenib was included in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2023) with an agreement valid until December 31, 2025 [1] - The first-line indication is expected to receive approval from the U.S. Food and Drug Administration in December 2024 [1] Group 3: Competitive Landscape - As of the announcement date, other ALK inhibitors available in Macao include Crizotinib, Ceritinib, Alectinib, Brigatinib, and Lorlatinib [1]

证券代码：300558 证券简称：贝达药业 公告编号：2025-047 二、药品概况及同类药品市场状况 贝达药业股份有限公司 关于澳门药物监督管理局批准盐酸恩沙替尼胶囊上市的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，中华人民共和国澳门特别行政区药物监督管理局（以下简称"ISAF"） 官方网站公示，ISAF 批准贝达药业股份有限公司（以下简称"公司"）申报 的盐酸恩沙替尼胶囊（商品名：贝美纳®，以下简称"恩沙替尼"）上市。本 次获批的适应症为：本品单药适用于间变性淋巴瘤激酶（ALK）阳性的局部晚期 或转移性的非小细胞肺癌（NSCLC）患者的治疗。现将具体情况公告如下： 一、药品信息 产品名称：盐酸恩沙替尼胶囊 药品类别：新药 持有人：贝达药业股份有限公司 恩沙替尼是一种新型强效、高选择性的新一代 ALK 抑制剂，是公司和控股子 公司 Xcovery Holdings, Inc.（以下简称"Xcovery"）共同开发的自主创新药。2020 年 11 月，恩沙替尼"适用于此前接受过克唑替尼治疗后进展的或者对克唑替尼不 耐受的 ALK 阳性的局部晚期 ...

2025 年 07 月 02 日 双融日报 --鑫融讯 分析师：万蓉 S1050511020001 wanrong@cfsc.com.cn 市场情绪：74 分（较热） 最近一年大盘走势 资料来源：Wind，华鑫证券研究 -15 -10 -5 0 5 10 15 20 25 (%) 沪深300 相关研究 ▌ 华鑫市场情绪温度指标：（较热） 华鑫市场情绪温度指标显示，昨日市场情绪综合评分为 74 分，市场情绪处于"较热"。历史市场情绪趋势变化可参 考图表 1。 ▌ 热点主题追踪 今日热点主题：光伏、能源金属、创新药 宏观经济意外下滑、地缘政治风险、流动性收紧超预期、行 业政策低于预期。 策 略 研 c 1、光伏主题：据上海有色网了解，为破除"内卷式"竞 争，近日国内头部光伏玻璃企业计划自 7 月开始集体减产 30％，此外部分玻璃企业堵口计划开始增多，预计后续国内 光伏玻璃供应量将快速下滑，国内供需失衡的状况将获得改 善，预计 7 月国内玻璃产量将下降至 45GW 左右。相关标的： 石英股份（603688）、爱旭股份（600732） 2、能源金属主题：刚果金公布，2025 年 6 月 21 日起， 战略矿产市场监管 ...